JP2024514844A5 - - Google Patents

Info

Publication number
JP2024514844A5
JP2024514844A5 JP2023561783A JP2023561783A JP2024514844A5 JP 2024514844 A5 JP2024514844 A5 JP 2024514844A5 JP 2023561783 A JP2023561783 A JP 2023561783A JP 2023561783 A JP2023561783 A JP 2023561783A JP 2024514844 A5 JP2024514844 A5 JP 2024514844A5
Authority
JP
Japan
Application number
JP2023561783A
Other languages
Japanese (ja)
Other versions
JPWO2022213204A5 (https=
JP2024514844A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2022/050536 external-priority patent/WO2022213204A1/en
Publication of JP2024514844A publication Critical patent/JP2024514844A/ja
Publication of JP2024514844A5 publication Critical patent/JP2024514844A5/ja
Publication of JPWO2022213204A5 publication Critical patent/JPWO2022213204A5/ja
Pending legal-status Critical Current

Links

JP2023561783A 2021-04-07 2022-04-07 Ｍｙｔ１阻害剤を含む併用治療 Pending JP2024514844A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171955P 2021-04-07 2021-04-07
US63/171,955 2021-04-07
PCT/CA2022/050536 WO2022213204A1 (en) 2021-04-07 2022-04-07 Combination therapies including myt1 inhibitors

Publications (3)

Publication Number Publication Date
JP2024514844A JP2024514844A (ja) 2024-04-03
JP2024514844A5 true JP2024514844A5 (https=) 2025-04-03
JPWO2022213204A5 JPWO2022213204A5 (https=) 2025-04-03

Family

ID=83544890

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561783A Pending JP2024514844A (ja) 2021-04-07 2022-04-07 Ｍｙｔ１阻害剤を含む併用治療

Country Status (6)

Country Link
US (1) US20240207300A1 (https=)
EP (1) EP4319752A4 (https=)
JP (1) JP2024514844A (https=)
CN (1) CN117729920A (https=)
CA (1) CA3214900A1 (https=)
WO (1) WO2022213204A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12435090B2 (en) 2021-10-04 2025-10-07 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use
CN119451958A (zh) * 2022-07-12 2025-02-14 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物
KR20250094718A (ko) * 2022-11-08 2025-06-25 제노 매니지먼트, 인크. Wee1 억제제로 암을 치료하기 위한 예측 바이오마커로서 시클린 e1 상태의 용도
WO2024104282A1 (zh) * 2022-11-14 2024-05-23 捷思英达控股有限公司 一种1H-吡咯并[2,3-b]吡啶衍生物、其制备方法及其在医药上的应用
EP4624471A4 (en) * 2022-11-25 2026-03-18 Shanghai Qilu Pharmaceutical Res And Development Centre Ltd PKMYT1 INHIBITOR, ITS PREPARATION PROCESS, PHARMACEUTICAL COMPOSITION, AND ITS USE
JP2025542335A (ja) * 2022-12-22 2025-12-25 リペア セラピューティクス インコーポレイテッド Ｍｙｔ１阻害剤である２－アミノ－１－（３－ヒドロキシ－２，６－ジメチルフェニル）－５，６－ジメチル－１Ｈ－ピロロ－［２，３－ｂ］ピリジン－３－カルボキサミドを作製する方法
WO2024153249A1 (zh) * 2023-01-20 2024-07-25 杭州英创医药科技有限公司 作为pkmyt1抑制剂的化合物
WO2024160683A1 (en) * 2023-01-30 2024-08-08 Ecole Polytechnique Federale De Lausanne (Epfl) Pou5f1b inhibitors
WO2024179948A1 (en) * 2023-02-28 2024-09-06 F. Hoffmann-La Roche Ag Indazole compounds as pkmyt1 kinase inhibitors
AU2024231943A1 (en) * 2023-03-09 2025-10-16 Cancer Research Technology Limited Biarylamide derivatives and their use as pkmyt1 inhibitors
TW202444721A (zh) * 2023-05-12 2024-11-16 智擎生技製藥股份有限公司 稠合吡咯環或稠合吡啶環之化合物
CN121358735A (zh) * 2023-07-04 2026-01-16 杭州领业医药科技有限公司 Rp-6306的晶型及其制备方法和用途
WO2025040014A1 (zh) * 2023-08-18 2025-02-27 英矽智能科技知识产权有限公司 并环化合物及其制备方法和用途
IL326854A (en) * 2023-09-14 2026-04-01 Debiopharm Int Sa Combination of WEE1 inhibitor and PKMYT1 inhibitor
WO2025060975A1 (en) * 2023-09-18 2025-03-27 Insilico Medicine Ip Limited Novel compounds as pkmyt1 inhibitors and use thereof
WO2025074271A1 (en) * 2023-10-02 2025-04-10 Repare Therapeutics Inc. Myt1 inhibitors for the treatment of cancers harboring replication stress mutations
WO2025074275A1 (en) * 2023-10-02 2025-04-10 Repare Therapeutics, Inc. Combination therapies including myt1 inhibitors and wee1 inhibitors
WO2025106635A1 (en) * 2023-11-15 2025-05-22 Zeno Management, Inc. Alteration of f-box and wd repeat domain containing 7 (fbxw7) gene as a predictive biomarker for treating cancer with wee1 inhibitors
KR20250088374A (ko) * 2023-12-08 2025-06-17 인제대학교 산학협력단 Ezh2 저해제 및 mettl3 억제제를 포함하는 암의 예방 또는 치료용 약제학적 조성물
WO2025182927A1 (ja) * 2024-02-27 2025-09-04 中外製薬株式会社 Ｍｙｔ１阻害剤の用途
WO2025188680A1 (en) * 2024-03-04 2025-09-12 Cardiff Oncology, Inc. Use of plk1 inhibitor in combination of gemcitabine or carboplatin in treating ovarian carcinoma
WO2025237957A1 (en) * 2024-05-14 2025-11-20 Institut Curie Composition for treatment of estrogen-dependent cancer comprising a mettl-3 inhibitor and a topoisomerase-1 inhibitor
US20260034078A1 (en) 2024-07-31 2026-02-05 Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud Xpg inhibitor compounds and the use thereof in the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033837A2 (en) * 1998-12-07 2000-06-15 Smithkline Beecham Corporation Myt1 kinase inhibitors
WO2016104777A1 (ja) * 2014-12-26 2016-06-30 国立大学法人九州大学 がんの処置のための方法
CN115811976A (zh) * 2020-04-01 2023-03-17 修复治疗公司 使用myt1抑制剂的方法
BR112022019611A2 (pt) * 2020-04-01 2022-11-29 Repare Therapeutics Inc Compostos, composições farmacêuticas e métodos para preparar compostos e seu uso

Similar Documents

Publication Publication Date Title
JP2024514844A5 (https=)
CL2025003768A1 (es) Sistema y métodos de cribado estático
CL2025002614A1 (es) Sistema y método de control para un sistema de vías ferroviarias
CN307046679S (https=)
CN307046378S (https=)
CN307049750S (https=)
CN307049663S (https=)
CN307047041S (https=)
CN307047013S (https=)
BY13151U (https=)
CN307046388S (https=)
CN307046110S (https=)
CN307045947S (https=)
CN307045696S (https=)
CN307045395S (https=)
CN307045364S (https=)
CN307044783S (https=)
CN307044779S (https=)
CN307044736S (https=)
CN307044464S (https=)
CN307044212S (https=)
BY23963C1 (https=)
BY13176U (https=)
BY13175U (https=)
BY13174U (https=)